Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

Completed · Phase 2/Phase 3

Conditions studied: Secondary Immune Deficiency

In brief

To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy (replacement of antibodies, which are infection-fighting proteins) in patients with a type of blood cancer called lymphoma, who have been treated with rituximab (a type of chemotherapy) and have an abnormal immune system putting them at increased risk of infection.

Key facts

Study ID

NCT03211065

Run by

Rochester General Hospital

People needed

16

Starts

2017-07-21

Expected to finish

2019-11-01

Last updated by the study team

2021-04-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of B cell non-Hodgkin's lymphoma
• Medically stable
• Able to understand and willingness to sign a written informed consent
• Able to comply with study procedures

You may not qualify if…

• Previously diagnosed primary immunodeficiency
• Additional immunosuppressive states
• Ongoing therapy with Ig replacement

Where it is running

• Allergy and Immunology, 222 Alexander Street — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.